. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2016 May 4;4(5):917–923. doi: 10.1016/j.jaip.2016.02.018

Table 4.

Association of asthma medications with the risk of MI among active asthmatic patients

Medication	MI (n=46)	No MI (n=19)	Odds ratios (95%CI)	P-values^*
Any treatment:
Yes	34 (65%)	18 (35%)	0.16 (0.02, 1.31)	p=0.09
No	12 (92%)	1 (8%)	1.0 (referent)
ICS treatment:
Yes	22 (65%)	12 (35%)	0.53 (0.18, 1.60)	p=0.26
No	24 (77%)	7 (23%)	1.0 (referent)
SCS treatment:
Yes	2 (100%)	0 (0%)	-^**	-^**
No	44 (70%)	19 (30%)
SABA treatment:
Yes	29 (66%)	15 (34%)	0.45 (0.13, 1.60)	p=0.22
No	17 (81%)	4 (19%)	1.0 (referent)
LABA treatment:
Yes	12 (67%)	6 (33%)	0.76 (0.24, 2.46)	p=0.65
No	34 (72%)	13 (28%)	1.0 (referent)

p-values for comparison of active asthmatics with and without use of asthma medications (within 3 months prior to the index date of MI) derived from univariate (unmatched) logistic regression modeling;

^**

model estimates for testing the association between SCS treatment and MI risk were not presented due to small number of subjects with SCS treatment. MI: myocardial infarction; ICS: inhaled corticosteroid; SCS: systematic corticosteroid; SABA: short acting beta agonist; LABA: long acting beta agonist